Igor N. Bondarenko

1962 -

country of citizenship: Soviet Union, Ukraine

educated at: Zaporizhzhia State Medical University

occupation: physician, oncologist

Series

There is nothing here

Create a new serie

Works

There is nothing here

Create a new work

Articles 58

Date

Title

Authors

2019-04-29

Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial

Igor N. Bondarenko, Adrian Murray Brunt, Michelle E Melisko
2018-01-15

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts.

Elísabeth Pérez Ruiz, Genny Del Zotto, Alexander Eggermont, Paolo Antonio Ascierto, Andrzej Mackiewicz, Piotr Rutkowski, Antoni Ribas, Thomas F Gajewski, Keith Flaherty, Ester Simeone, Alessandra Cesano, Silvia C. Formenti, Matthew J Wongchenko, Jeffrey S Weber, Lisa H. Butterfield, Nicholas P. Restifo, Antonio M Grimaldi, Costanza M Cristiani, Igor N. Bondarenko, Claus Garbe, Luigi Fattore, Rita Mancini, Sandra Demaria, Monica Cantile, Michele Maio, Mario Mandala, Yibing Yan, Federica Fratangelo, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Francesca Capone, Laura Lattanzio, Hexiao Wang, Charlotte Proby, Nelofer Syed, Marcella Occelli, Carolina Cauchi, Marco Carlo Merlano, Catherine Harwood, Elisabetta Gambale, Consiglia Carella, Michele De Tursi, Maria Libera Ascierto, Claire Vanpouille-Box, Ciro Francesco Ruggiero, Maria Elena Pisanu, Grazia Sciancalepore, Michela Rovera, Chiara Varamo, Daniela Vivenza, Zelda Seia, Stefania Palazzini, Fabiana Errico, Davide Basso, Laura Quaranta, Fulvio Lavagna, Silvia Violante, Duane Moogk, Ivan Liadi, William Rittase, Victoria Fang, Janna Dougherty, Arianne Perez-Garcia, Iman Osman, Navin Varadarajan, Alan B Frey, Michelle Krogsgaard, Mariarosanna De Fina, Vito Vanella, Anna C Pavlick, Diana Giannarelli, Domenico Liguoro, Andrea Cerri, Gerardo Botti, Piera Maiolino, Dirk Schadendorf, Rossana Tallerico, Cinzia Garofalo, Elio Gulletta, Ennio Carbone, Maurizio Di Bonito, Roberta D’Aniello, Rubeta Matin
2017-07-01

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

Ana Arance, Georgina V. Long, Daniil Stroyakovskiy, Evgeny V Levchenko, Claus Garbe, Vanna Chiarion Sileni, Igor N. Bondarenko, Jochen Utikal, Caroline Robert
2017-09-01

A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer

Jaffer Ajani, Igor N. Bondarenko
2016-06-28

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18

Igor N. Bondarenko
2016-11-24

NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron

Igor N. Bondarenko, Cristina Marinela Oprean, Hope Rugo, Meinolf Karthaus
2016-01-22

A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma

Igor S. Bazin, Lucian Miron, Igor N. Bondarenko, Andrzej Deptała
2016-02-08

A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Igor N. Bondarenko
2016-03-02

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind

Igor N. Bondarenko, Sherene Loi, Marco Colleoni, Seock-Ah Im, Norikazu Masuda, Hiroji Iwata
2016-11-24

Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer.

Igor N. Bondarenko
2016-11-04

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

Igor N. Bondarenko, Denise A Yardley, Joyce O'Shaughnessy, Seock-Ah Im, Norikazu Masuda
2016-02-05

A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis

Igor N. Bondarenko, Rustem Khasanov
2016-08-08

Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients

Igor N. Bondarenko, Constantin Volovat
2015-01

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Igor N. Bondarenko
2015-10-26

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer

Igor N. Bondarenko, Joyce O'Shaughnessy
2015-05-01

Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer

Igor N. Bondarenko
2015-07-03

Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy

Constantin Volovat, Igor N. Bondarenko
2015-10-08

A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results

Robert J Jones, Igor N. Bondarenko
2015-12-14

A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel

Vladimir Moiseyenko, Igor N. Bondarenko
2015-05-31

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Filippo de Braud, Jean-Jacques Grob, Caroline Robert, Daniil Stroyakovskiy, Ana Arance, Virginia Ferraresi, Igor N. Bondarenko, Jochen Utikal, Georgina V. Long, Dirk Schadendorf, Keith Flaherty, Evgeny V Levchenko, Antoni Ribas, Axel Hauschild
2015-05-30

Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies

Igor N. Bondarenko
2015-03-17

Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.

Filippo de Braud, Jean-Jacques Grob, Igor N. Bondarenko, Ana Arance, Georgina V. Long, Caroline Robert, Daniil Stroyakovskiy, Dirk Schadendorf, Keith Flaherty, Evgeny V Levchenko, Antoni Ribas
2015-02-23

Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.

Michele Maio, Jean-Jacques Grob, Igor N. Bondarenko, Luc Thomas, Claus Garbe, Vanna Chiarion Sileni, Alessandro Testori, Tai-Tsang Chen, Jedd D Wolchok, Steinar Aamdal, Marina Tschaika
2015-05-21

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)

Igor N. Bondarenko, Enriqueta Felip, James Spicer
2015-05-13

Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy.

Vladimir Moiseyenko, Igor N. Bondarenko
2015-08-12

Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel

Igor N. Bondarenko
2014-04-25

Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer

Igor N. Bondarenko, Chandra Belani, Giorgio Scagliotti, Silvia Novello
2014-03-05

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

Igor N. Bondarenko, Cristina Marinela Oprean
2014-03-07

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

Igor N. Bondarenko
2014-01-09

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

Sergey Orlov, Igor N. Bondarenko, Maciej Krzakowski, Jean-Yves Douillard, Silvia Novello
2014-09-29

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

Caroline Robert, Jean-Jacques Grob, Dirk Schadendorf, Keith Flaherty, Daniil Stroyakovskiy, Ana Arance, Virginia Ferraresi, Evgeny V Levchenko, Igor N. Bondarenko, Jochen Utikal, Georgina V. Long, Filippo de Braud, Antoni Ribas, Axel Hauschild
2014-04-01

A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).

Igor N. Bondarenko

Human - wd:Q30957829

Welcome to Inventaire

the library of your friends and communities

learn more